We are delighted to announce that researchers from the Institute of Neuroscience have recently published in Alzheimer & Dementia. The article entitled “Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease” was led by Yasmine Salman, under the supervision of Bernard Hanseeuw.
Learn more about their research :
Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease
Abstract
INTRODUCTION
Magnetic resonance imaging (MRI) segmentation algorithms make it possible to study detailed medial temporal lobe (MTL) substructures as hippocampal subfields and amygdala subnuclei, offering opportunities to develop biomarkers for preclinical Alzheimer's disease (AD).
METHODS
We identified the MTL substructures significantly associated with tau-positron emission tomography (PET) signal in 581 non-demented individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI-3). We confirmed our results in our UCLouvain cohort including 110 non-demented individuals by comparing volumes between individuals with different visual Braak's stages and clinical diagnosis.
RESULTS
Four amygdala subnuclei (cortical, central, medial, and accessory basal) were associated with tau in amyloid beta-positive (Aβ+) clinically normal (CN) individuals, while the global amygdala and hippocampal volumes were not. Using UCLouvain data, we observed that both Braak I-II and Aβ+ CN individuals had smaller volumes in these subnuclei, while no significant difference was observed in the global structure volumes or other subfields.
CONCLUSION
Measuring specific amygdala subnuclei, early atrophy may serve as a marker of temporal tauopathy in preclinical AD, identifying individuals at risk of progression.
Full article: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14235